Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

NCT05181605 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Pancreatic Cancer Resectable

Interventions

DRUG: Folfirinox and Stereotactic Body Radiotherapy

Sponsor

Instituto de investigación e innovación biomédica de Cádiz